NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NovaBay Pharmaceuticals reports strong Q2 performance amidst market expansion

NovaBay Pharmaceuticals demonstrated strong performance in Q2 2024, driven by growth in eyecare products and improved gross margin.
While facing challenges such as net losses and low cash reserves, the company is focused on strategic transactions and market opportunities.
With a clear focus on the U.S. dry eye market and sales optimization, NovaBay is poised for continued growth and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

EMERYVILLE, Calif.--( BUSINESS WIRE )--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Audrey Kunin, MD will return for her fourth appearance this year on the QVC network. Dr. Kunin will discuss DERMAdoctor's moisturizing Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on “Give Gorgeous – Gifts With Purchase” hosted by two of QVC's most popular hosts, Jennifer Coffey and Terri Conn, on Saturday, November 19 at 4 p.m. Eastern time.

NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to the QVC® Network With DERMAdoctor's Eczema Balm

A 1-for-35 reverse split of NovaBay Pharmaceuticals (NBY) stock has gone into effect. These are the details.

NovaBay Pharmaceuticals (NBY) Stock: 1-For-35 Reverse Split Goes Into Effect

NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Justin Hall - Chief Executive Officer and General Counsel Andy Jones - Chief Financial Officer Conference Call Participants Good afternoon, and welcome to the NovaBay Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only-mode.

NovaBay Pharmaceuticals, Inc. (NBY) Q3 2022 Earnings Call Transcript

EMERYVILLE, Calif.--( BUSINESS WIRE )--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2022 and provides a business update. Financial results for the first nine months of 2022 include DERMAdoctor, which NovaBay acquired on November 5, 2021.

NovaBay Pharmaceuticals Reports Third Quarter 2022 Financial Results

EMERYVILLE, Calif.--( BUSINESS WIRE )--NovaBay® Pharmaceuticals, Inc. (the “Company”) (NYSE American: NBY) announces that today, following approval from the Company's stockholders obtained at the Company's November 10, 2022 special stockholders' meeting, the Company's Board of Directors (the “Board”) has approved the filing of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect a 1-for-35 reverse stock split of all outstanding shares of common stock of the Company. The Company anticipates that the 1-for-35 reverse stock split will be effective as of 4:15 p.m. New York City Time on Tuesday, November 15, 2022 (the “Effective Date”), and the Company's common stock will begin trading on a split-adjusted basis on Wednesday, November 16, 2022.

NovaBay Pharmaceuticals Announces 1-for-35 Reverse Stock Split

NovaBay Pharmaceuticals to Hold Third Quarter 2022 Conference Call on November 14

NovaBay Pharmaceuticals Announces Expansion of DERMAdoctor Picture Porefect Collection with Launch of 15% Niacinamide Pore Minimizing Serum

NovaBay Pharmaceuticals to Present at the LD Micro Main Event XV

NovaBay Pharmaceuticals Announces Significant Orders for DERMAdoctor's Top-Selling Kakadu C Anti-Aging Serum ahead of the Holiday Season

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals' Avenova and DERMAdoctor products featured during Amazon Early Access Prime event.

NovaBay Pharmaceuticals' Avenova® and DERMAdoctor® Products to be Featured During the October 11-12 Amazon Prime Early Access Sale

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on October 3, 2022 it received a notice from the NYSE American LLC that the Company's common stock has been selling for a low price per share for a substantial period of time. As a result, pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the Company must effect a reverse stock split of its common stock or otherwise demonstrate sustained price improvement within a reasonable

NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Low Share Price

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). The conference is being held at the Sofitel Hotel New York. A webcast of the presentation will be available on t

NovaBay Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders: To My Fellow Stockholders: Over the past year, we have successfully transformed NovaBay from a single product company into a larger organization with three brands in three distinct market segments. We are a stronger company with established brands in the large and growing eyecare, skincare and wound care mark

NovaBay Pharmaceuticals CEO Issues Letter to Stockholders

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present at the Virtual Life Sciences Investor Forum on Thursday, September 15, 2022 at 1:00 p.m. Eastern time (10:00 a.m. Pacific Time). Management will be holding investor one-on-one meetings on September 16 and September 19-20. Investors can registe

NovaBay Pharmaceuticals to Present at the Virtual Life Sciences Investor Forum

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that Chief Product Officer Audrey Kunin, MD will return to the QVC network for her third on-air appearance this year to discuss DERMAdoctor's revolutionary Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm. This problem-solving eczema treatment will be

NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Showcase DERMAdoctor's Eczema Balm on Return QVC® Appearance

The stock price of NovaBay Pharmaceuticals (NBY) fell by 13.03% yesterday. This is what happened.

NovaBay Pharmaceuticals (NBY) Stock Falls 13.03%: What Happened

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals Enters Into Agreements For a Private Placement and Warrant Reprice Transactions To Raise Up to $5.3 Million

NovaBay Pharmaceuticals Enters Into Agreements For a Private Placement and Warrant Reprice Transactions To Raise Up to $5.3 Million

NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Justin Hall - Chief Executive Officer and General Counsel Andy Jones - Chief Financial Officer Kim Shartsis - Vice President of Commercial Conference Call Participants Operator Welcome to the NovaBay Pharmaceuticals Second Quarter 2020 Financial Results Conference Call. At this time, all participants are in listen-only-mode.

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q2 2022 Results - Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2022 and provides a business update. Financial results for the first six months of 2022 include the operations of the DERMAdoctor business, which was acquired on November 5, 2021. “The strategy to expand and diversify our portfolio of high-quality products is paying off with product revenue increasing 43% over the prior year. We are also

NovaBay Pharmaceuticals Reports Second Quarter 2022 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2022 after market close on Thursday, August 11, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time:   Thursday, August 11, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration:   Participants can pre-register for the conference call here:   Callers who pre-reg

NovaBay Pharmaceuticals to Hold Second Quarter 2022 Conference Call on August 11

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals targets the lash extension market with antimicrobial Avenova lid and lash spray.

NovaBay Pharmaceuticals Targets New Market with Antimicrobial Avenova® Lid and Lash Spray for Lash Extensions

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the availability of select DERMAdoctor products at two popular U.S. online retailers, Target.com and Urbanoutfitters.com. “DERMAdoctor products provide innovative, highly effective, problem-solving solutions for common skin conditions that are often overlooked in the skin

NovaBay Pharmaceuticals' DERMAdoctor Products Now Available at Target.com and Urbanoutfitters.com

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces record sales of Avenova-branded products during Amazon's Prime Day event (July 12-13). Sales of Avenova-branded products during the two-day event increased 27% over Prime Days 2021 and 48% over Prime Days 2020, and reached a new one-day all-time high since the product bec

NovaBay Pharmaceuticals Reports Record Avenova® Sales During Amazon's Prime Day Event

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that its DERMAdoctor product collections will be featured at Cosmoprof North America, a leading business-to-business (B2B) beauty trade show being held July 12-14 at the Las Vegas Convention Center. “We're thrilled about connecting in-person with retailers and other profe

NovaBay Pharmaceuticals' DERMAdoctor Products to be Featured at Leading B2B Beauty Trade Show Cosmoprof North America

NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Justin Hall - Chief Executive Officer and General Counsel Andy Jones - Chief Financial Officer Conference Call Participants Destiny Hance - Ladenburg Thalmann Edward Woo - Ascendiant Capital Markets Operator Good afternoon and welcome to NovaBay Pharmaceuticals First Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode.

News for NovaBay Pharmaceuticals Stock (NBY)